Iovance Biotherapeutics, Inc. (IOVA) Monday said the Food and Drug Administration (FDA) has lifted a partial clinical hold placed on the registrational IOV-LUN-202 study of its LN-145 TIL cell therapy in non-small cell lung cancer (NSCLC).
After reviewing the company's proposal to develop additional safety measures and monitoring, the FDA has cleared Iovance to resume patient enrollment in IOV-LUN-202, the company said in a statement.
In December last year, the FDA had placed a clinical hold on the IOV-LUN-202 trial in response to a Grade 5 (fatal) serious adverse event potentially related to non-myeloablative lymphodepletion pre-conditioning regimen.
The company expects to complete enrollment in the IOV-LUN-202 registrational study in 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.